If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
165
results.
Updated on
19/04/2026 [07:25:00]
Results 125 to 150 of 165
Absstract of: CN121570577A
The invention relates to application of insulin and analogues thereof in preparation of medicines for preventing or treating Alzheimer's disease. Researches find that the damage effect of A beta on insulin secretion depends on CX3CR1, the blood plasma insulin level of AD model mice can be recovered by supplementing exogenous insulin, and the A beta has the treatment effects of improving cognitive impairment of AD model mice, improving cerebrovascular lesion, recovering brain glycometabolism function, relieving brain inflammatory response and the like; the invention provides an alternative medicine with definite curative effect, high safety and affordable price for Alzheimer's disease, expands the indications of insulin and analogues thereof, and has wide market prospect and important social significance.
Absstract of: CN121575099A
The invention belongs to the field of biomedicine, and particularly relates to application of miRNA-219a-2-3p in diagnosis and treatment of Parkinson's disease. Relates to application of the reagent in preparation of a Parkinson's disease detection kit. The reagent comprises the following components: (1) miRNA-219a-2-3p or/and a mimic substance thereof; or/and (2) a reagent for detecting the miRNA-219a-2-3p or/and the mimic substance of the miRNA-219a-2-3p. The invention further relates to application of an inhibitor of the miRNA-219a-2-3 in preparation of a medicine for treating the Parkinson's disease. The invention provides a new technical scheme for Parkinson's disease diagnosis and treatment.
Absstract of: CN121570448A
The invention discloses application of glutaric acid or medicinal salt thereof in medicine, a medicine composition and a medicine preparation, and belongs to the field of medicine application. According to the application of the glutaric acid or the medicinal salt thereof in preparing the medicine for inhibiting neurodegeneration, promoting lysosomal activity and treating the Alzheimer's disease, a new potential treatment medicine is provided for treatment of the Alzheimer's disease, and a more effective scheme for treating the Alzheimer's disease is provided.
Absstract of: US20260055131A1
0000 The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzogquinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below.
0000
0000 The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
Absstract of: US20260053846A1
The disclosure provides polymeric compounds that inhibit binding of an amyloid-β-oligomer to cellular prior protein, methods for identifying such compounds, and their therapeutic use. In particular, the present disclosure provides a collection of anionic polymers and methods of using these compounds to treat amyloid-related disorders, e.g., Alzheimer's disease.
Absstract of: US20260053747A1
The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.
Absstract of: US20260055090A1
Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Absstract of: US20260053847A1
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheimer's disease (disease-modifying drug) contains hydrogen gas as an active ingredient.
Absstract of: US20260053792A1
Compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof are provided. Specifically, a compound having a structure represented by general formula I, and a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof, or a mixture thereof are provided. The compound promotes transcription factor EB (TFEB) nuclear translocation and lysosome generation, and can be used for preventing, treating, or assisting in treating various diseases related to lysosome dysfunction and biosynthesis insufficiency, especially neurodegenerative diseases caused by the accumulation of intracerebral pathological proteins (e.g., β-amyloid protein and α-synuclein), such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Absstract of: US20260055402A1
Among other things, the present disclosure provides various oligonucleotide technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing such oligonucleotide compositions. In some embodiments, a method is a method of treatment or prevention of Huntington's Disease in a subject in need thereof; a method of allele-specific knockdown of a mutant Huntingtin transcript in a subject; a method for delaying the onset of and/or reducing the severity of at least one symptom of Huntington's Disease in a subject with Huntington's Disease; a method of reducing the expression, level, amount and/or activity of a mutant Huntingtin gene or a gene product thereof; and/or a method of preparation of a medicament for treatment of Huntington's Disease, wherein the method pertains to the use of an oligonucleotide described herein, administered at a dose described herein. In some embodiments, the present disclosure provides doses, dosages, and formulations of an oligonucleotide described herein.
Absstract of: US20260055403A1
Methods for treating and/or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.
Absstract of: US20260053782A1
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of “wearing-off”, the treatment comprising administering more than N doses of levodopa per day to provide a total daily dose of X mg of levodopa and administering a single daily dose of Y mg of opicapone, wherein X is from 100 to 1000, N is from 2 to 10 and Y is from 25 to 50.
Absstract of: WO2026044269A1
Pharmaceutical compositions that include a benzimidazole, benzimidazole derivative, or a metabolite thereof and a selenium source, and their use in methods of treating, Alzheimer's disease, Parkinson's disease, frontotemporal lobe dementia, dementia, cognitive decline, neural injury, neurodegeneration, and/or a neurodegenerative and/or neuropsychiatric condition, a neurodegenerative and/or neuropsychiatric disease, and/or a neurodegenerative and/or neuropsychiatric disorder in a subject are described herein.
Absstract of: WO2026041069A1
Provided herein are pharmaceutical compositions comprising thermoresponsive polymer and uses thereof. Specifically, provided herein are pharmaceutical compositions comprising a mitochondrial uncoupler and a thermoresponsive polymer and uses thereof. Such pharmaceutical compositions can be useful for treating diseases, such as but not limited to NASH, overweight, obesity, medical complications related to overweight or obesity, type 2 diabetes (T2D), and Alzheimer's disease and related dementias (AD/ADRD).
Absstract of: WO2026044051A1
CD9 expressing microglia are observed in various human neurodegenerative diseases beyond traumatic brain injuries, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CD9 blocking and FcγRIII blocking methods can be widely used as an intervention strategy to prevent disease-associated cognitive impairment. Therefore, disclosed herein are methods for treating a traumatic brain injury in a subject in need thereof that involve the step of administering to the subject a therapeutically effective amount of a composition comprising an anti-CD9 or an anti FcγRIII blocking agent, such as a blocking antibody.
Absstract of: US2024368188A1
0000 6,7-Dihydrothiazolo5,4-cpyridines substituted in the 5-position with heterocyclic rings are positive allosteric modulators of the muscarinic acetylcholine receptor Ma (mAChR MA) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.
Absstract of: US2024368188A1
0000 6,7-Dihydrothiazolo5,4-cpyridines substituted in the 5-position with heterocyclic rings are positive allosteric modulators of the muscarinic acetylcholine receptor Ma (mAChR MA) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.
Absstract of: EP4700016A2
It is an object of the present invention to provide a novel pharmaceutical agent or method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof, wherein the agent can be administered particularly to patients obtaining high therapeutic effects, among ALS patients who require treatments. According to the present invention, there is provided a pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing the disease progress thereof or treating symptoms caused by amyotrophic lateral sclerosis or suppressing the disease progress thereof, which comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, wherein the agent is administered by repeating a 14-day administration period and a 14-day drug holiday period, or by establishing an initial 14-day administration period and an initial 14-day drug holiday period and then repeating an administration period for 10 out of 14 days and a 14-day drug holiday period, and wherein a patient administered with the agent complies with specific criteria.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP4700020A1
Provided in the present invention are a heterocyclic compound as a TYK2 inhibitor, and synthesis, and use thereof.. Specifically, provided is a compound or a pharmaceutically acceptable salt thereof. The compound is as represented by formula A, and each group is as defined herein.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: CN121550230A
The invention relates to an isotope labeled trapidil derivative. In particular, isotope labeled trapidil derivatives useful in the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are provided. The isotope labeled trapidil derivative comprises a deuterated trapidil derivative. In addition, combination therapies of isotopically labeled trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are also provided.
Absstract of: CN121550227A
The invention relates to application of 1-allyl piperazine or pharmaceutically acceptable salt thereof in preparation of a medicine for treating Parkinson's disease. A caenorhabditis elegans PD model is adopted to prove for the first time that on one hand, 1-allyl piperazine can obviously enhance autophagy activity in a model animal body, efficiently promote removal of aggregation alpha-synuclein and radically relieve damage of Parkinson's disease characteristic pathological protein deposition to neurons, and on the other hand, 1-allyl piperazine can effectively promote removal of aggregation alpha-synuclein and radically relieve damage of Parkinson's disease characteristic pathological protein deposition to neurons. The compound can effectively activate mitochondrial unfolded protein reaction. The autophagy activation pathway and the mitochondrial function regulation pathway can generate a synergistic effect to jointly relieve the neurodegeneration process related to the Parkinson's disease, so that dopaminergic neurons are protected, and the pathological progress of the disease is delayed.
Nº publicación: CN121554405A 24/02/2026
Applicant:
UNIV XI AN JIAOTONG
\u897F\u5B89\u4EA4\u901A\u5927\u5B66
Absstract of: CN121554405A
The invention belongs to the technical field of medicine research, and particularly relates to a hydrogen sulfide donor compound, a pharmaceutical composition containing the hydrogen sulfide donor compound and a synthetic method and application of the pharmaceutical composition. The hydrogen sulfide donor compound has a structure as shown in a general formula (I), and the hydrogen sulfide donor compound can responsively release H2S under physiological conditions, especially in the presence of endogenous mercaptan, and can realize bifunctional release by introducing a drug active fragment. Experimental results show that the compound is stable in H2S release behavior and excellent in biocompatibility, reduces the occurrence rate of aortic dissection and improves Alzheimer's disease and Parkinson's disease in animal experiments, has potential application value in prevention and treatment of cardiovascular diseases and neurodegenerative diseases, and has broad application prospects. Meanwhile, the strain also has an expansion potential for other diseases related to oxidative stress; .
BOPI
Electronic site
